Biotechnology News and Research

RSS

Positive interim results from Medicago's H5N1 vaccine Phase I human clinical trial

Medicago Inc. a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results from a Phase I human clinical trial with its H5N1 Avian Influenza vaccine candidate ("H5N1 vaccine"). The vaccine was found to be safe, well tolerated and also induced a solid immune response.

21 Dec 2009

Seattle Genetics and GSK sign ADC collaboration agreement

Seattle Genetics, Inc., announced today that it has entered into a collaboration agreement with GlaxoSmithKline (GSK) under which GSK will pay an upfront fee of $12 million for rights to utilize Seattle Genetics’ antibody-drug conjugate (ADC) technology with multiple antigens to be named by GSK.

21 Dec 2009

Soligenix commences SGX201 Phase 1/2 clinical trial for acute radiation enteritis prevention

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has initiated a Phase 1/2 clinical trial evaluating SGX201, a time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP), for the prevention of acute radiation enteritis.

21 Dec 2009

'Help is Here Express' helps uninsured and financially-struggling patients with free prescription medicines

The Beaches Leader recently reported that the "Help is Here Express" bus tour visited Jacksonville Beach's Mission House to help uninsured and financially-struggling patients access information on programs that provide prescription medicines for free or nearly free.

19 Dec 2009

STERIPLEX HC kills MRSA and other pathogens in record time

STERIPLEX® Health Care (HC) is a new Sterilant/Sporicide, Tuberculocide, and Bactericide, which has recently received Federal EPA Registration. STERIPLEX® HC sets new standards, killing MRSA, spores and other pathogens in a fraction of the time of competing products while remaining safe to people and the environment.

18 Dec 2009

GSK receives European CHMP positive opinion for Revolade

Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has received a positive opinion for Revolade® (eltrombopag/Promacta®) from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).

18 Dec 2009

PolyMedix completes first two segments of its PMX-30063 antibiotic drug candidate Phase 1B study

PolyMedix, Inc., an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, has successfully completed the first two segments of a Phase 1B clinical safety study with its novel antibiotic drug candidate PMX-30063.

18 Dec 2009

Leerink Swann announces availability of its 2010 healthcare investment outlook report

Leerink Swann, the leading healthcare-focused investment banking firm, today announced the availability of the firm’s 2010 healthcare investment outlook report.

18 Dec 2009

Ocimum Biosolutions ranked 42nd on the Deloitte Technology Fast 500 Asia Pacific 2009

Ocimum Biosolutions, a leading integrated genomics company, today announced that it ranked 42nd on the Deloitte Technology Fast 500 Asia Pacific 2009, a ranking of the 500 fastest growing technology companies in Asia Pacific. Rankings are based on percentage revenue growth over three years. In addition to ranking on Deloitte’s Technology Fast 500, Ocimum ranked fourth on the Technology Fast 50 India Program, which is a ranking of the 50 fastest growing technology firms in India.

18 Dec 2009

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

18 Dec 2009

Patheon announces fiscal 2009 fourth-quarter and full-year financial results

Patheon a global provider of drug development and manufacturing services to the international pharmaceutical industry today announced results for the fourth quarter and full year ended October 31, 2009.

18 Dec 2009

Biovator and BASF sign collaboration agreement to develop In Vitro test systems

The Sweden-based biotech company Biovator and the global chemical industry leader BASF have signed a collaboration agreement for final development of In Vitro test systems capable of identifying the potential of chemical compounds to induce allergic reaction in humans. The agreement also includes a five-year BASF option of final product deliveries.

18 Dec 2009

Opexa Therapeutics completes registered direct offering

Opexa Therapeutics, Inc., a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today announced that it has completed its registered direct offering with several institutional investors to sell 2,550,000 units, each unit consisting of one share of Opexa common stock, a five-year Series

18 Dec 2009

TSI organizes clinical, research and educational programs

The Wake Forest University Translational Science Institute (TSI) has announced a number of organizational changes. Four programs and four specialized centers have been organized to function collaboratively in support of research conducted at Wake Forest University Baptist Medical Center.

18 Dec 2009

Umbilical cord stem cells may be useful in treating blood disorders

Stem cells that could one day provide therapeutic options for muscle and bone disorders can be easily harvested from the tissue of the umbilical cord, just as the blood that goes through it provides precursor cells to treat some blood disorders, said University of Pittsburgh School of Medicine researchers in the online version of the Journal of Biomedicine and Biotechnology.

18 Dec 2009

BioMS Medical invests in Spectral Diagnostics to advance treatment for sepsis

Spectral Diagnostics Inc. and BioMS Medical Corp. today announced that BioMS Medical ("BioMS") and a syndicate of investors have invested $14 million in Spectral Diagnostics ("Spectral", or the "Company") to advance Toraymyxin(TM), a treatment for severe sepsis, towards regulatory approval and commercialization in the United States.

18 Dec 2009

Regado Biosciences announces completion of Series D financing

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, today announced the completion of a $40 million Series D financing.

18 Dec 2009

Healthnostics' MedGuardian system targets the needs of hospitalists

Healthnostics, Inc., a medical and biotechnology analytics company today announced the inclusion of a hospitalist (hospital employed physicians, physician assistants and nurse practitioners) focus for the MedGuardian patient clinical monitoring and risk management system.

18 Dec 2009

Roche Diagnostics and Takara Bio enter into license agreement

Roche Diagnostics and Takara Bio, the Shiga (Japan)-based supplier of systems for use in life science research, announced that they have entered into a license agreement for use of the melting curve analysis technology and SYBR Green techniques in their Kits and Instruments for Real Time PCR.

From Roche Sequencing and Life Science 18 Dec 2009

Ligand Pharmaceuticals, Neurogen revise merger agreement

Ligand Pharmaceuticals Incorporated and Neurogen Corporation announced today they have amended their merger agreement to increase the merger consideration payable

18 Dec 2009